Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gptkb:monoclonal_antibody |
| gptkbp:administeredBy |
intravenous infusion
|
| gptkbp:approvedBy |
gptkb:FDA
2021 |
| gptkbp:ATCCode |
C10AX20
|
| gptkbp:brand |
gptkb:Evkeeza
|
| gptkbp:CASNumber |
1643489-24-0
|
| gptkbp:developedBy |
gptkb:Regeneron_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
evinacumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
IgG4 monoclonal antibody
|
| gptkbp:mechanismOfAction |
ANGPTL3 inhibitor
|
| gptkbp:pregnancyCategory |
not assigned
|
| gptkbp:prescribes |
adults
children aged 5 years and older |
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
dizziness fatigue nasopharyngitis influenza-like illness |
| gptkbp:target |
ANGPTL3
|
| gptkbp:UNII |
6Z1Y2V4S2E
|
| gptkbp:usedFor |
gptkb:homozygous_familial_hypercholesterolemia
|
| gptkbp:bfsParent |
gptkb:Evkeeza
|
| gptkbp:bfsLayer |
8
|